Deerborne Group to Attend ASCO 2026 and Highlight AI Platform COMPASS 360

May 26, 2026
The Deerborne Group announced that its senior leadership will attend the American Society of Clinical Oncology 2026 Annual Meeting in Chicago, where the firm will highlight its AI-enabled COMPASS 360 platform for diagnostics strategy and decision-making.

The Deerborne Group announced in a press release that its senior leadership will attend the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which will take place from May 29 to June 2 in Chicago, Illinois.

At the event, the firm expects discussions to center on clinical utility, reimbursement strategy, regulatory expectations, and the integration of artificial intelligence with digital pathology and molecular diagnostics. The Deerborne Group will also present its COMPASS 360 platform, a strategic intelligence system powered by AI that combines market, clinical, competitive, reimbursement, and commercialization insights to support decision-making for diagnostics companies and investors.

The Deerborne Group provides consulting services to Fortune 500 companies, molecular diagnostics laboratories, biotechnology firms, and investment organizations, focusing on commercialization strategy, reimbursement, operational planning, and corporate growth in precision diagnostics.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

05/26
Brain Navi Introduces NaoTrac Surgical Robot for Precision Neurosurgery
05/26
Neurophet and VHIR Begin Joint Study on AI Imaging for Multiple Sclerosis
05/26
Insilico Medicine and Human Longevity Partner on AI Foundation Model for Longevity Science
05/26
Parkinson's Foundation Identifies 2,000 Participants for Neuron23 Trial Through PD Trial Navigator
05/26
Octagos Launches Ask Atlas for Cardiac Device Clinics

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like